<?xml version="1.0" encoding="UTF-8"?>
<p id="para0009">In the case of ATMPs using cells, tissues, human blood or blood components as starting materials, the same European legislation is applicable for their donation, procurement or collection, testing, traceability and coding [
 <xref rid="bib0018" ref-type="bibr">18</xref>,
 <xref rid="bib0026" ref-type="bibr">26</xref>]. Concerning the requirements for processing ATMPs, Good Manufacturing Practice-compliant facilities are required, and the principles of Good Manufacturing Practice should be followed 
 <xref rid="bib0027" ref-type="bibr">[27]</xref>, especially those specific to ATMPs 
 <xref rid="bib0028" ref-type="bibr">[28]</xref>. The clinical use of ATMPs must follow the Regulation 536/2014 on clinical trials 
 <xref rid="bib0029" ref-type="bibr">[29]</xref>—when ATMPs are still considered investigational medicinal products—or they have to be granted marketing authorization by the European Commission via a centralized procedure, as mentioned previously. Spain, as a member of the EU, regulates ATMPs, cell and tissue transplants and transfusion medicine according to EU legislation.
</p>
